Contributors: La Jolla Institute for Immunology La Jolla, CA, États-Unis; University of California San Diego (UC San Diego); University of California (UC); King‘s College London; Cancer Research UK London Research Institute; The Francis Crick Institute London; Mayo Clinic Rochester; University of Georgia USA; Vanderbilt University Medical Center Nashville; Vanderbilt University Nashville; UCB Pharma Slough; UCB Pharma Brussels; Genmab B.V. Utrecht, Netherlands; Genmab A/S (global headquarters) Denmark (Genmab); Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology; Institut Pasteur Paris (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); University of Tokyo Tokyo = Tōkyō teikoku daigaku (UTokyo); Ragon Institute of MGH, MIT and Harvard; Hôpital Henri Mondor; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Moderna Inc Cambridge, MA, USA; University of Miami; Institut Pasteur du Cambodge; Pasteur Network (Réseau International des Instituts Pasteur); National Institute of Allergy and Infectious Diseases Bethesda (NIAID-NIH); National Institutes of Health Bethesda, MD, USA (NIH); Invenra Inc Madison, Wisconsin, USA; F-Star Therapeutics Cambridge, United Kingdom; IGM Biosciences Mountain View, California, USA; Lava Therapeutics Utrecht, Netherlands; Walter Reed Army Institute of Research; Henry M. Jackson Foundation for the Advancement of Military Medicine (HJM); Adimab Mountain View, California, USA; Donnelly Center Cellular and Biomolecular Research Univ. Toronto; University of Toronto; University of Oxford; Generate:Biomedicines Somerville, Massachusetts, USA; Merus N.V. Utrecht, Netherlands; Regeneron Pharmaceuticals Tarrytown, NY; Mabylon AG Schlieren, Suisse; T. Cantaert is an HHMI/Welcome Trust international research scholar (208710/Z/17/Z) and is supported by NIH grant U01AI151758–01.
نبذة مختصرة : International audience ; Therapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27–30, 2022, experts in antibody research across academia and industry met for the Keystone symposium “Antibodies as Drugs” to present the state-of-the-art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering.
Processing Request
No Comments.